GlobeNewswire 11-Aug-2017 10:21 AM
PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc.(NYSE MKT:HEB) (the Company or Hemispherx) announced today that it anticipates filing its 2017 second quarter financial results for quarter ended June 30 on Monday, August 14, 2017. Hemispherx will host a conference call at 1:00 p.m. Eastern Daylight Time (EDT) on Tuesday, August 15, 2017 to provide a general business update. Hemispherx will respond to various stockholder questions submitted prior to the call.
An audio replay of the conference call will be available on the Companys website approximately one hour following the conclusion of the call.
Conference Call Information
|Date:||Tuesday, August 15, 2017|
|Time:||1:00 PM EDT|
|Dial-in numbers:||800-346-7359 (domestic)|
|Questions:||firstname.lastname@example.org by 5:00 PM EDT on Monday, August 14, 2017|
About Hemispherx BiopharmaHemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherxs flagship products include Alferon N Injection and the experimental therapeutic rintatolimod (tradenames Ampligen or Rintamod). Rintatolimod is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Hemispherxs platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Because rintatolimod is experimental in nature, it is not designated safe and effective by the FDA for general use and is legally available only through clinical trials.
Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.hemispherx.net. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
Company/Investor Contact Charles Jones CJones & Associates Public Relations Office: 888-557-6480 Cell: 305-987-7418 Email: email@example.com
Source: Hemispherx Biopharma, Inc.